Updates to the Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. Clinicians would benefit from additional education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
Category
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.
Category
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 2.25 AAPA Category 1 CME credit
  • 2.25 ACPE contact hours
  • 2.25 AMA PRA Category 1 Credit™
  • 2.25 ANCC contact hours
  • 2.25 Participation
Cost $0.00
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia
As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00